-
1
-
-
0034471796
-
Molecular mechanisms of tumor angiogenesis and tumor progression
-
DOI 10.1023/A:1006414621286
-
Cavallaro U, Christofori G: Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 50: 63-70, 2000 (Pubitemid 32166291)
-
(2000)
Journal of Neuro-Oncology
, vol.50
, Issue.1-2
, pp. 63-70
-
-
Cavallaro, U.1
Christofori, G.2
-
2
-
-
0036984640
-
Role of angiogenesis in tumor growth and metastasis
-
Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002
-
(2002)
Semin Oncol
, vol.29
, pp. 15-18
-
-
Folkman, J.1
-
3
-
-
14644440555
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
-
DOI 10.1200/JCO.2005.06.081
-
Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005 (Pubitemid 46202320)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.5
, pp. 1011-1027
-
-
Hicklin, D.J.1
Ellis, L.M.2
-
4
-
-
13444278498
-
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
-
Gerber HP, Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680, 2005
-
(2005)
Cancer Res
, vol.65
, pp. 671-680
-
-
Gerber, H.P.1
Ferrara, N.2
-
6
-
-
33846638744
-
Risks of Proteinuria and Hypertension with Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis
-
DOI 10.1053/j.ajkd.2006.11.039, PII S0272638606018336
-
Zhu X, Wu S, Dahut WL, Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193, 2007 (Pubitemid 46178407)
-
(2007)
American Journal of Kidney Diseases
, vol.49
, Issue.2
, pp. 186-193
-
-
Zhu, X.1
Wu, S.2
Dahut, W.L.3
Parikh, C.R.4
-
7
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
-
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26: 2013-2019, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Diaz-Rubio, E.3
Scheithauer, W.4
Figer, A.5
Wong, R.6
Koski, S.7
Lichinitser, M.8
Yang, T.S.9
Rivera, F.10
Couture, F.11
Sirzen, F.12
Cassidy, J.13
-
8
-
-
56749161699
-
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
-
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26: 5422-5428, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 5422-5428
-
-
Rini, B.I.1
Halabi, S.2
Rosenberg, J.E.3
Stadler, W.M.4
Vaena, D.A.5
Ou, S.S.6
Archer, L.7
Atkins, J.N.8
Picus, J.9
Czaykowski, P.10
Dutcher, J.11
Small, E.J.12
-
9
-
-
0042343801
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
-
DOI 10.1056/NEJMoa021491
-
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434, 2003 (Pubitemid 36910021)
-
(2003)
New England Journal of Medicine
, vol.349
, Issue.5
, pp. 427-434
-
-
Yang, J.C.1
Haworth, L.2
Sherry, R.M.3
Hwu, P.4
Schwartzentruber, D.J.5
Topalian, S.L.6
Steinberg, S.M.7
Chen, H.X.8
Rosenberg, S.A.9
-
10
-
-
2942657615
-
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
-
DOI 10.1200/JCO.2004.11.022
-
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191, 2004 (Pubitemid 41095154)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.11
, pp. 2184-2191
-
-
Johnson, D.H.1
Fehrenbacher, L.2
Novotny, W.F.3
Herbst, R.S.4
Nemunaitis, J.J.5
Jablons, D.M.6
Langer, C.J.7
DeVore III, R.F.8
Gaudreault, J.9
Damico, L.A.10
Holmgren, E.11
Kabbinavar, F.12
-
11
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
-
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370: 2103-2111, 2007
-
(2007)
Lancet
, vol.370
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
Ravaud, A.4
Bracarda, S.5
Szczylik, C.6
Chevreau, C.7
Filipek, M.8
Melichar, B.9
Bajetta, E.10
Gorbunova, V.11
Bay, J.O.12
Bodrogi, I.13
Jagiello-Gruszfeld, A.14
Moore, N.15
-
12
-
-
40749158416
-
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
-
Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, Chen H, Stadler WM, Vokes EE: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). ASCO Meeting Abstracts 25: 7526, 2007
-
(2007)
ASCO Meeting Abstracts
, vol.25
, pp. 7526
-
-
Karrison, T.1
Kindler, H.L.2
Gandara, D.R.3
Lu, C.4
Guterz, T.L.5
Nichols, K.6
Chen, H.7
Stadler, W.M.8
Vokes, E.E.9
-
13
-
-
35548941394
-
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B CALGB
-
Cancer & Leukemia Group B
-
Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM, Cancer & Leukemia Group B: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB. ASCO Meeting Abstracts 25: 4508, 2007
-
(2007)
ASCO Meeting Abstracts
, vol.25
, pp. 4508
-
-
Kindler, H.L.1
Niedzwiecki, D.2
Hollis, D.3
Oraefo, E.4
Schrag, D.5
Hurwitz, H.6
McLeod, H.L.7
Mulcahy, M.F.8
Schilsky, R.L.9
Goldberg, R.M.10
-
14
-
-
54249120945
-
Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO
-
Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, Tomczak P, Taran T, Harbeck N, Steger GG: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. ASCO Meeting Abstracts 26: LBA1011, 2008
-
(2008)
ASCO Meeting Abstracts
, vol.26
-
-
Miles, D.1
Chan, A.2
Romieu, G.3
Dirix, L.Y.4
Cortes, J.5
Pivot, X.6
Tomczak, P.7
Taran, T.8
Harbeck, N.9
Steger, G.G.10
-
15
-
-
62449124416
-
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil
-
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 1227-1234
-
-
Reck, M.1
Von Pawel, J.2
Zatloukal, P.3
Ramlau, R.4
Gorbounova, V.5
Hirsh, V.6
Leighl, N.7
Mezger, J.8
Archer, V.9
Moore, N.10
Manegold, C.11
-
16
-
-
65549150854
-
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
-
Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27: 2231-2237, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 2231-2237
-
-
Van Cutsem, E.1
Vervenne, W.L.2
Bennouna, J.3
Humblet, Y.4
Gill, S.5
Van Laethem, J.L.6
Verslype, C.7
Scheithauer, W.8
Shang, A.9
Cosaert, J.10
Moore, M.J.11
-
17
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004 (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
18
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544, 2007
-
(2007)
J Clin Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
O'Dwyer, P.J.4
Mitchell, E.P.5
Alberts, S.R.6
Schwartz, M.A.7
Benson III, A.B.8
-
19
-
-
20544478429
-
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
-
DOI 10.1200/JCO.2005.05.112
-
Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23: 3697-3705, 2005 (Pubitemid 46252464)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.16
, pp. 3697-3705
-
-
Kabbinavar, F.F.1
Schulz, J.2
McCleod, M.3
Patel, T.4
Hamm, J.T.5
Hecht, J.R.6
Mass, R.7
Perrou, B.8
Nelson, B.9
Novotny, W.F.10
-
20
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676, 2007
-
(2007)
N Engl J Med
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
Dickler, M.4
Cobleigh, M.5
Perez, E.A.6
Shenkier, T.7
Cella, D.8
Davidson, N.E.9
-
21
-
-
20044364346
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
-
Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799, 2005
-
(2005)
J Clin Oncol
, vol.23
, pp. 792-799
-
-
Miller, K.D.1
Chap, L.I.2
Holmes, F.A.3
Cobleigh, M.A.4
Marcom, P.K.5
Fehrenbacher, L.6
Dickler, M.7
Overmoyer, B.A.8
Reimann, J.D.9
Sing, A.P.10
Langmuir, V.11
Rugo, H.S.12
-
22
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
DOI 10.1056/NEJMoa061884
-
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550, 2006 (Pubitemid 44917502)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.24
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
Lilenbaum, R.7
Johnson, D.H.8
-
23
-
-
66149147757
-
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer
-
Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Chu L, Azar CA, Wolmark N: Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27: 3385-3390, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 3385-3390
-
-
Allegra, C.J.1
Yothers, G.2
O'Connell, M.J.3
Sharif, S.4
Colangelo, L.H.5
Lopa, S.H.6
Petrelli, N.J.7
Goldberg, R.M.8
Atkins, J.N.9
Seay, T.E.10
Fehrenbacher, L.11
O'Reilly, S.12
Chu, L.13
Azar, C.A.14
Wolmark, N.15
-
24
-
-
50649095801
-
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
-
Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26: 4708-4713, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 4708-4713
-
-
Cohen, E.E.1
Rosen, L.S.2
Vokes, E.E.3
Kies, M.S.4
Forastiere, A.A.5
Worden, F.P.6
Kane, M.A.7
Sherman, E.8
Kim, S.9
Bycott, P.10
Tortorici, M.11
Shalinsky, D.R.12
Liau, K.F.13
Cohen, R.B.14
-
25
-
-
74949119167
-
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors
-
Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP: Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28: 207-214, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 207-214
-
-
Lockhart, A.C.1
Rothenberg, M.L.2
Dupont, J.3
Cooper, W.4
Chevalier, P.5
Sternas, L.6
Buzenet, G.7
Koehler, E.8
Sosman, J.A.9
Schwartz, L.H.10
Gultekin, D.H.11
Koutcher, J.A.12
Donnelly, E.F.13
Andal, R.14
Dancy, I.15
Spriggs, D.R.16
Tew, W.P.17
-
26
-
-
68749117496
-
Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma
-
Jonkers IJ, van Buren M: Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. Clin Exp Nephrol 13: 397-401, 2009
-
(2009)
Clin Exp Nephrol
, vol.13
, pp. 397-401
-
-
Jonkers, I.J.1
Van Buren, M.2
-
27
-
-
39649122843
-
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
-
Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD: A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100: 282-284, 2008
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 282-284
-
-
Patel, T.V.1
Morgan, J.A.2
Demetri, G.D.3
George, S.4
Maki, R.G.5
Quigley, M.6
Humphreys, B.D.7
-
28
-
-
0037370325
-
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases
-
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716, 2003
-
(2003)
J Clin Invest
, vol.111
, pp. 707-716
-
-
Eremina, V.1
Sood, M.2
Haigh, J.3
Nagy, A.4
Lajoie, G.5
Ferrara, N.6
Gerber, H.P.7
Kikkawa, Y.8
Miner, J.H.9
Quaggin, S.E.10
-
29
-
-
2442707596
-
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology
-
Schrijvers BF, Flyvbjerg A, De Vriese AS: The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65: 2003-2017, 2004
-
(2004)
Kidney Int
, vol.65
, pp. 2003-2017
-
-
Schrijvers, B.F.1
Flyvbjerg, A.2
De Vriese, A.S.3
-
30
-
-
40849130173
-
VEGF inhibition and renal thrombotic microangiopathy
-
DOI 10.1056/NEJMoa0707330
-
Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358: 1129-1136, 2008 (Pubitemid 351398487)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.11
, pp. 1129-1136
-
-
Eremina, V.1
Jefferson, J.A.2
Kowalewska, J.3
Hochster, H.4
Haas, M.5
Weisstuch, J.6
Richardson, C.7
Kopp, J.B.8
Kabir, M.G.9
Backx, P.H.10
Gerber, H.-P.11
Ferrara, N.12
Barisoni, L.13
Alpers, C.E.14
Quaggin, S.E.15
-
31
-
-
33846484966
-
Renal thrombotic microangiopathy caused by anti-VEGF antibody treatment for metastatic renal-cell carcinoma
-
Frangie C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D: Renal thrombotic microangiopathy caused by anti-VEGF antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 8: 177-178, 2007
-
(2007)
Lancet Oncol
, vol.8
, pp. 177-178
-
-
Frangie, C.1
Lefaucheur, C.2
Medioni, J.3
Jacquot, C.4
Hill, G.S.5
Nochy, D.6
-
32
-
-
34247597779
-
Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma
-
Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH: Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 3: 287-293, 2007
-
(2007)
Nat Clin Pract Nephrol
, vol.3
, pp. 287-293
-
-
Roncone, D.1
Satoskar, A.2
Nadasdy, T.3
Monk, J.P.4
Rovin, B.H.5
-
33
-
-
56549115248
-
Glomerular disease related to anti-VEGF therapy
-
Stokes MB, Erazo MC, D'Agati VD: Glomerular disease related to anti-VEGF therapy. Kidney Int 74: 1487-1491, 2008
-
(2008)
Kidney Int
, vol.74
, pp. 1487-1491
-
-
Stokes, M.B.1
Erazo, M.C.2
D'Agati, V.D.3
-
34
-
-
58449096748
-
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib
-
Bollee G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P, Noel LH, Knebelmann B: Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 24: 682-685, 2009
-
(2009)
Nephrol Dial Transplant
, vol.24
, pp. 682-685
-
-
Bollee, G.1
Patey, N.2
Cazajous, G.3
Robert, C.4
Goujon, J.M.5
Fakhouri, F.6
Bruneval, P.7
Noel, L.H.8
Knebelmann, B.9
-
35
-
-
33751403599
-
Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group
-
discussion 174
-
Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, Pummer K, Zigeuner R: Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 51: 168-173, discussion 174, 2007
-
(2007)
Eur Urol
, vol.51
, pp. 168-173
-
-
Schips, L.1
Dalpiaz, O.2
Lipsky, K.3
Langner, C.4
Rehak, P.5
Puerstner, P.6
Pummer, K.7
Zigeuner, R.8
-
36
-
-
0021070402
-
Use of single voided urine samples to estimate quantitative proteinuria
-
Ginsberg JM, Chang BS, Matarese RA, Garella S: Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 309: 1543-1546, 1983
-
(1983)
N Engl J Med
, vol.309
, pp. 1543-1546
-
-
Ginsberg, J.M.1
Chang, B.S.2
Matarese, R.A.3
Garella, S.4
-
37
-
-
72449132908
-
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
-
Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC: VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 46: 439-448, 2010
-
(2010)
Eur J Cancer
, vol.46
, pp. 439-448
-
-
Izzedine, H.1
Massard, C.2
Spano, J.P.3
Goldwasser, F.4
Khayat, D.5
Soria, J.C.6
-
38
-
-
0347453077
-
Selecting and appraising studies for a systematic review
-
Meade MO, Richardson WS: Selecting and appraising studies for a systematic review. Ann Intern Med 127: 531-537, 1997
-
(1997)
Ann Intern Med
, vol.127
, pp. 531-537
-
-
Meade, M.O.1
Richardson, W.S.2
-
39
-
-
12344312699
-
-
Available at: Accessed September 15, 2009
-
National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://safetyprofiler-ctep.nci.nih.gov/CTC/CTC. aspx. Accessed September 15, 2009
-
Common Terminology Criteria for Adverse Events V3.0 (CTCAE)
-
-
-
40
-
-
85190701314
-
-
Available at Accessed September 1, 2009
-
Biostat I: Comprehensive Meta-analysis. 2006. Available at www.meta-analysis.com. Accessed September 1, 2009
-
(2006)
Biostat I: Comprehensive Meta-analysis
-
-
-
42
-
-
66149133167
-
International multi-centre randomised Phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial
-
Price TJ, Gebski V, van Hazel GA, Robinson BA, Broad A, Ganju V, Cunningham D, Wilson K, Tunney V, Tebbutt NC: International multi-centre randomised Phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial. ASCO Meeting Abstracts 26: 4029, 2008
-
(2008)
ASCO Meeting Abstracts
, vol.26
, pp. 4029
-
-
Price, T.J.1
Gebski, V.2
Van Hazel, G.A.3
Robinson, B.A.4
Broad, A.5
Ganju, V.6
Cunningham, D.7
Wilson, K.8
Tunney, V.9
Tebbutt, N.C.10
-
43
-
-
36048982143
-
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
-
Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A: Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25: 4743-4750, 2007
-
(2007)
J Clin Oncol
, vol.25
, pp. 4743-4750
-
-
Herbst, R.S.1
O'Neill, V.J.2
Fehrenbacher, L.3
Belani, C.P.4
Bonomi, P.D.5
Hart, L.6
Melnyk, O.7
Ramies, D.8
Lin, M.9
Sandler, A.10
-
44
-
-
0037208589
-
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
-
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65, 2003
-
(2003)
J Clin Oncol
, vol.21
, pp. 60-65
-
-
Kabbinavar, F.1
Hurwitz, H.I.2
Fehrenbacher, L.3
Meropol, N.J.4
Novotny, W.F.5
Lieberman, G.6
Griffing, S.7
Bergsland, E.8
|